PT  - JOURNAL ARTICLE
AU  - Anda Bularga
AU  - Rong Bing
AU  - Anoop SV Shah
AU  - Philip D Adamson
AU  - Miles Behan
AU  - David E Newby
AU  - Andrew Flapan
AU  - Neal Uren
AU  - Nick Cruden
TI  - Clinical outcomes following balloon aortic valvuloplasty
AID  - 10.1136/openhrt-2020-001330
DP  - 2020 Sep 01
TA  - Open Heart
PG  - e001330
VI  - 7
IP  - 2
4099  - http://openheart.bmj.com/content/7/2/e001330.short
4100  - http://openheart.bmj.com/content/7/2/e001330.full
SO  - Open Heart2020 Sep 01; 7
AB  - Background Balloon aortic valvuloplasty (BAV) remains a treatment option for the selected patients with severe aortic stenosis. We examined clinical outcomes and predictors of prognosis in patients undergoing BAV for severe aortic stenosis.Methods We identified all patients undergoing BAV from January 2010 to March 2018 (n=167) at a single transcatheter aortic valve implantation (TAVI) centre. Patient demographics, investigations, subsequent interventions and clinical outcomes were obtained from electronic health records.Results Patients undergoing BAV were elderly (median age 80, IQR 73–86 years) and half (n=87, 52%) were male. All-cause mortality at 30 days and 12 months was 11% and 43%, respectively. Reduce ejection fraction (EF 30%–50%: HR 1.76, 95% CI 1.05 to 2.94; EF <30%: HR 1.90, 95% CI 1.12 to 3.20) was the only independent predictor at baseline of overall mortality. Median survival was 212 (IQR 54–490) days from the index procedure. Mortality at 1 year was lowest in patients who subsequently underwent TAVI or SAVR but high among those who had no further interventions or those who had a repeat BAV (14%, 19%, 60%, 89% respectively, log-rank p<0.001).Conclusion BAV as a bridge to definitive aortic valve intervention in carefully selected patients offers acceptable outcomes. These contemporary observational findings demonstrate the ongoing potential utility of BAV in the TAVI era.